UNSPSC 51332202: Carpipramine

This classification denotes an antidepressant agent with the molecular formula C28H38N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8AFK6F91EQ, chemically known as 5h-dibenz(b,f)azepine, 10,11-dihydro-5-(3-(4-piperidino-4-carbamoylpiperidino)propyl)- but generally known as carpipramine, which bears US NIH Compound Identifier 2580. Carpipramine most often comes in base, dihydrochloride, hydrochloride, and maleate forms.

UNSPSC 51332202 Carpipramine (Commodity) does not align with the state and local procurement activity currently tagged under this code. The recent opportunities associated with it involve naloxone procurement, direct-to-manufacturer pharmacy initiatives, and generic multi-source pharmaceutical distribution — none of which involve carpipramine specifically. Carpipramine is a tricyclic antidepressant with limited modern clinical use, yet the code's recent solicitations focus on emergency opioid-reversal agents, pharmacy benefit program modernization, and bulk generic pharmaceutical supply agreements across state and local health systems. The issuing bodies span county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local government facilities across multiple states including Oregon). The work being solicited involves procurement of finished pharmaceuticals and medical devices for distribution through existing wholesaler networks or direct-to-manufacturer channels, coupled with compliance certifications in Good Manufacturing Practices, Drug Supply Chain Security Act adherence, and FDA regulatory requirements.

Activity under this code is geographically dispersed across Florida, Texas, and Minnesota, with the most recent solicitations reflecting a shift toward alternative pharmaceutical distribution models and emergency health-response products rather than legacy antidepressant pharmaceuticals. Seminole County issued an IFB (No. IFB60459723LAS) on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries due by July 26, 2023 — notably with a due date predating the posting date, signaling a data inconsistency in the source. The Minnesota Multistate Cooperative Purchasing Alliance released an RFP (S1070000015802) on January 20, 2026, establishing multi-award contracts for generic pharmaceuticals and OTC products through authorized wholesalers, with proposals due March 26, 2026, and performance weighted 75 percent on price competitiveness. Texas HHS issued an RFI (HHS0017013) on April 3, 2026, exploring vendor capacity for direct-to-manufacturer prescription programs outside traditional PBM and wholesaler channels. The code's current activity shows minimal direct relevance to carpipramine procurement and substantial mismatch between the code's nominal scope and recent state and local buying patterns.